Myosin Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Myosin Therapeutics's estimated annual revenue is currently $930k per year.
- Myosin Therapeutics's estimated revenue per employee is $77,500
Employee Data
- Myosin Therapeutics has 12 Employees.
- Myosin Therapeutics grew their employee count by 20% last year.
Myosin Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | Co-Founder and President Board Directors | Reveal Email/Phone |
2 | Co-Founder and Secretary Board Directors | Reveal Email/Phone |
3 | Co-Founder and President | Reveal Email/Phone |
4 | Investor Relations | Reveal Email/Phone |
Myosin Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $15.3M | 99 | 5% | N/A | N/A |
#2 | $1.1M | 7 | -30% | N/A | N/A |
#3 | $3.7M | 24 | 4% | N/A | N/A |
#4 | $4.3M | 28 | -3% | N/A | N/A |
#5 | $2.5M | 16 | N/A | N/A | N/A |
#6 | $0.8M | 5 | 0% | N/A | N/A |
#7 | $1.1M | 7 | 0% | N/A | N/A |
#8 | $2.5M | 16 | 7% | N/A | N/A |
#9 | $1.4M | 9 | -25% | N/A | N/A |
#10 | $0.6M | 4 | 0% | N/A | N/A |
What Is Myosin Therapeutics?
The mission of Myosin Therapeutics, Inc. is to improve health outcomes through the development of novel pharmacotherapies targeting members of the myosin family of molecular motors. Myosin Therapeutics is positioned as the first nanomotor platform company focused on oncology, with a proprietary nMotor system for drug discovery. nMotor is a full screening platform from HTS to validation and target selectivity profiling, enabling Myosin to develop a robust pipeline of oncology therapeutics. Myosin has used nMotor to develop a unique therapeutic to improve outcomes in Glioblastoma (GBM), a critical unmet need with a conservative estimated serviceable market of at least 10,000 cases yearly in the US alone. Additionally, Myosin is developing a unique neurotherapeutic to prevent relapse in METH use disorder, another critical unmet need. METH use disorder is a chronic disorder for which there are currently no FDA-approved medications. More broadly, preclinical studies indicate that first-in-class pharmacotherapeutics targeting NMII have value in many applications, including other substance use disorders, cancer, neural regeneration and infectious diseases. Further, approval of a clinically safe NMII inhibitor will enable scientific advancements into the study of NMII’s contribution to human physiology, such as learning and memory.
keywords:N/AN/A
Total Funding
12
Number of Employees
$930k
Revenue (est)
20%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.3M | 12 | N/A | N/A |
#2 | $1.8M | 12 | N/A | N/A |
#3 | $1M | 12 | -20% | N/A |
#4 | $1.9M | 12 | 9% | N/A |
#5 | $2M | 14 | -7% | N/A |